Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 75 of 348 entries
View as:

REGN7508 Versus Apixaban and Enoxaparin for Thromboprophylaxis After Total Knee Arthroplasty in Adults

Phase: N/A Priority: Normal
NCT ID: NCT07015905 Org: User:
Start: 06/30/25 End: 05/12/27 Due: 05/12/28

Expanded Access to REGN4461 for Patients With Lipodystrophy or Monogenic Obesity With Complications of Leptin Deficiency or Deficient Leptin Signaling

Phase: N/A Priority: Normal
NCT ID: NCT04710056 Org: User:
Start: - End: - Due: -

Compassionate Use of Dupilumab

Phase: N/A Priority: Normal
NCT ID: NCT04776694 Org: User:
Start: - End: - Due: -

Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy

Phase: N/A Priority: Normal
NCT ID: NCT02326220 Org: User:
Start: 03/31/15 End: 04/30/16 Due: 04/30/17

A Study of Alirocumab in Participants With Autosomal Dominant Hypercholesterolemia (ADH) and Gain-of-Function Mutations (GOFm) of the Proprotein Convertase Subtilisin Kexin 9 (PCSK9) Gene or Loss-of-Function Mutations (LOFm) of the Apolipoprotein (Apo) B Gene

Phase: N/A Priority: Normal
NCT ID: NCT01604824 Org: User:
Start: 02/22/12 End: 07/28/17 Due: 07/28/18

Safety, Pharmacokinetics and Efficacy of Dupilumab in Patients ≥6 Months to <6 Years With Moderate-to-Severe Atopic Dermatitis (Liberty AD PRESCHOOL)

Phase: N/A Priority: Normal
NCT ID: NCT03346434 Org: User:
Start: 11/30/17 End: 07/08/21 Due: 07/08/22

Study of a High-Dose Aflibercept in Participants With Diabetic Eye Disease

Phase: N/A Priority: Normal
NCT ID: NCT04429503 Org: User:
Start: 06/29/20 End: 06/18/24 Due: 06/18/25

DME And VEGF Trap-Eye [Intravitreal Aflibercept Injection (IAI;EYLEA®;BAY86-5321)] INvestigation of Clinical Impact

Phase: N/A Priority: Normal
NCT ID: NCT00789477 Org: User:
Start: 12/31/08 End: 09/30/10 Due: 09/30/11

A Study to Assess the Safety and Tolerability of Single Ascending Doses of REGN1033(SAR391786)

Phase: N/A Priority: Normal
NCT ID: NCT01507402 Org: User:
Start: 01/31/12 End: 11/30/12 Due: 11/30/13

A Trial to Learn How the Combination of Fianlimab With Cemiplimab and Chemotherapy Works Compared With Cemiplimab and Chemotherapy for Treating Adult Patients With Advanced Non-small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT05800015 Org: User:
Start: 08/08/23 End: 12/23/31 Due: 12/23/32

Study to Assess the Safety and Tolerability of Multiple Ascending Doses of REGN1500

Phase: N/A Priority: Normal
NCT ID: NCT02107872 Org: User:
Start: 04/30/14 End: 09/30/15 Due: 09/30/16

Dupilumab As An Adjunct For Subcutaneous Grass Immunotherapy

Phase: N/A Priority: Normal
NCT ID: NCT03558997 Org: User:
Start: 06/07/18 End: 06/13/19 Due: 06/13/20

Compassionate Use of Pozelimab

Phase: N/A Priority: Normal
NCT ID: NCT05232110 Org: User:
Start: - End: - Due: -

Study of the Safety and Efficacy of REGN1033 (SAR391786) in Patients With Sarcopenia

Phase: N/A Priority: Normal
NCT ID: NCT01963598 Org: User:
Start: 11/30/13 End: 02/28/15 Due: 02/28/16

REGN5381 in Adult Participants With Uncontrolled Hypertension

Phase: N/A Priority: Normal
NCT ID: NCT06833190 Org: User:
Start: 04/16/25 End: 07/24/26 Due: 07/24/27

Study Assessing the Safety, Tolerability, Pharmacokinetics, and Immunogenicity of Repeated Subcutaneous Doses of Anti-Spike (S) SARS-CoV-2 Monoclonal Antibodies (REGN10933+REGN10987) in Adult Volunteers as Related to COVID-19

Phase: N/A Priority: Normal
NCT ID: NCT04519437 Org: User:
Start: 07/26/20 End: 11/22/21 Due: 11/22/22

Evaluate the Long-Term Safety and Efficacy of Evinacumab in Patients With Homozygous Familial Hypercholesterolemia

Phase: N/A Priority: Normal
NCT ID: NCT03409744 Org: User:
Start: 03/13/18 End: 04/13/23 Due: 04/13/24

Neoadjuvant Cemiplimab for the Treatment of Resectable NSCLC, HCC, and HNSCC in Adult Patients

Phase: N/A Priority: Normal
NCT ID: NCT03916627 Org: User:
Start: 07/23/19 End: 05/14/30 Due: 05/14/31

Study to Assess the Safety, Tolerability, Pharmacokinetic, and Pharmacodynamic Effects of a Single Dose of REGN5713-5714-5715 in Healthy Adult Participants

Phase: N/A Priority: Normal
NCT ID: NCT03969849 Org: User:
Start: 06/03/19 End: 03/27/20 Due: 03/27/21

Phase 1 Safety Study With Intravitreal (IVT) REGN2176-3 in Patients Aged 50 Years and Older With Wet AMD

Phase: N/A Priority: Normal
NCT ID: NCT02061865 Org: User:
Start: 02/28/14 End: 12/31/14 Due: 12/31/15

Study of Safety, Tolerability, and Pharmacokinetics of REGN3470-3471-3479 in Healthy Adult Volunteers

Phase: N/A Priority: Normal
NCT ID: NCT02777151 Org: User:
Start: 05/27/16 End: 04/26/17 Due: 04/26/18

A Study to Test if Trevogrumab or Trevogrumab With Garetosmab When Taken With Semaglutide is Safe and How Well They Work in Adult Patients With Obesity for Weight Loss and Fat Loss

Phase: N/A Priority: Normal
NCT ID: NCT06299098 Org: User:
Start: 03/13/24 End: 11/20/26 Due: 11/20/27

An Observational Study to Investigate the Use of Aflibercept 8 mg to Treat Adult Patients With Neovascular Age-Related Macular Degeneration (nAMD) and Diabetic Macular Edema (DME) in a Real-World Setting

Phase: N/A Priority: Normal
NCT ID: NCT06398080 Org: User:
Start: 12/12/24 End: 01/03/29 Due: 01/03/30

Study to Assess the Efficacy of Anti-Bet v 1 Monoclonal Antibodies in Adults to Reduce Symptoms of Seasonal Allergic Rhinitis

Phase: N/A Priority: Normal
NCT ID: NCT04709575 Org: User:
Start: 01/14/21 End: 08/24/21 Due: 08/24/22

First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS)

Phase: N/A Priority: Normal
NCT ID: NCT06351592 Org: User:
Start: 08/28/24 End: 04/26/29 Due: 04/26/30